Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung

Inclusion Criteria:

Advanced adenocarcinoma of lung, measurable disease
Non-smoker, or former light (less than 10 pack years and stopped at least 15 years); OR
patients with known EGFR activating mutation regardless of smoking status
ECOG(Eastern Cooperative Oncology Group) 0-1.

Cohort B (select sites only): patients with HER2 amplified or HER2 mutation-positive NSCLC; may have had prior therapy

Exclusion Criteria:

Active brain metastases
Prior systemic therapy for advanced disease in Cohort A only. Cohort B can have had any number of prior lines of systemic therapy.
known EGFR wild type NSCLC